Verition Fund Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Verition Fund Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-126,300	Closed	-$2.72M	–	2327
2025 Q4	$2.72M	Buy	+126,300	New	+$2.45M	0.01%	1333
2023 Q1	–	Sell	-141,600	Closed	-$1.01M	–	2150
2022 Q4	$1.01M	Hold	141,600	–	–	0.02%	905
2022 Q3	$709K	Buy	+141,600	New	+$779K	0.01%	1646

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Verition Fund Management's AVDL Position: Q1 2026 in Review

Verition Fund Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 450,981 shares — an estimated $9.72M sold.

Verition Fund Management first reported a position in AVDL in Q3 2024 and held it in 5 quarters. The position peaked at $9.72M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Verition Fund Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Verition Fund Management sold 450,981 Avadel Pharmaceuticals shares in Q1 2026, an estimated $9.72M.
Verition Fund Management first reported a position in Avadel Pharmaceuticals in Q3 2024 and held it in 5 quarters.
Verition Fund Management's Avadel Pharmaceuticals position peaked at $9.72M in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.